Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severely Active Rheumatoid Arthritis Receiving Methotrexate

NCT04312815 is registered in ClinicalTrials.gov with SinoMab BioScience Ltd as lead sponsor.

NCT NCT04312815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04312815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severely Active Rheumatoid Arthritis Receiving Methotrexate
Lead sponsor
SinoMab BioScience Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
December 28, 2017
Completion date
July 31, 2022
Enrollment
510 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis(ra)